Choroideremia

With the December 2017 announcement that the world’s first ocular gene therapy had received approval by the U.S. Food and Drug Administration (FDA), there’s no doubt that 2017 was a landmark year…

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the…

In many retinal diseases, vision loss occurs when cells that are crucial for vision are damaged or lost. This is the case, for example, in age-related macular degeneration (AMD), retinitis pigmentosa, choroideremia,…

Stem cell therapy has emerged as one of the most promising approaches in the fight to end blindness, and Dr. Gilbert Bernier’s research has played an enormous role in pushing the field…

Dr. Brian Ballios has restored vision in mice, but he is not stopping there. He is on a mission to develop stem cell therapies for people living with blindness and has a…

So far this year, the pace of vision research has been sizzling! To celebrate the arrival of sizzling weather, we asked Fighting Blindness Canada (FBC) staff to share their favourite FBC science…